源自himbacine的凝血酶受体拮抗剂：vorapaxar的C7-氨甲基和C9a-羟基类似物。
Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar.
作者信息
Chelliah Mariappan V, Chackalamannil Samuel, Xia Yan, Greenlee William J, Ahn Ho-Sam, Kurowski Stan, Boykow George, Hsieh Yunsheng, Chintala Madhu
机构信息
Merck Research Laboratories , 2015 Galloping Hill Road, Kenilworth, New Jersey 07033-1300, United States.
出版信息
ACS Med Chem Lett. 2013 Dec 18;5(2):183-7. doi: 10.1021/ml400452v. eCollection 2014 Feb 13.
Abstract
We have synthesized several C7-aminomethyl analogues of vorapaxar that are potent PAR-1 antagonists. Many of these analogues showed excellent in vitro binding affinity and pharmacokinetics profile in rats. Compound 6a from this series showed excellent PAR-1 activity (K i = 5 nM). We have also synthesized a C9a-hydroxy analogue of vorapaxar, which showed very good PAR-1 affinity (K i = 19.5 nM) along with excellent rat pharmacokinetic profile and ex vivo efficacy in the cynomolgus monkey.
摘要
我们合成了几种vorapaxar的C7-氨甲基类似物，它们是有效的PAR-1拮抗剂。这些类似物中的许多在大鼠中显示出优异的体外结合亲和力和药代动力学特征。该系列中的化合物6a显示出优异的PAR-1活性（K i = 5 nM）。我们还合成了一种vorapaxar的C9a-羟基类似物，它显示出非常好的PAR-1亲和力（K i = 19.5 nM），同时在食蟹猴中具有优异的大鼠药代动力学特征和体内外疗效。
相似文献
1
Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar.源自himbacine的凝血酶受体拮抗剂：vorapaxar的C7-氨甲基和C9a-羟基类似物。
ACS Med Chem Lett. 2013 Dec 18;5(2):183-7. doi: 10.1021/ml400452v. eCollection 2014 Feb 13.
2
Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar.源自辛巴生的凝血酶受体拮抗剂：沃拉帕沙的C7-螺环类似物。
ACS Med Chem Lett. 2014 Mar 11;5(5):561-5. doi: 10.1021/ml500008w. eCollection 2014 May 8.
3
Discovery of nor-seco himbacine analogs as thrombin receptor antagonists.发现诺塞考他宾类似物作为凝血酶受体拮抗剂。
Bioorg Med Chem Lett. 2012 Apr 1;22(7):2544-9. doi: 10.1016/j.bmcl.2012.01.138. Epub 2012 Feb 16.
4
Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand.涉及人血小板蛋白酶激活受体-4通过其连接配体类似物的激活的分子要求。
Platelets. 2017 Dec;28(8):812-821. doi: 10.1080/09537104.2017.1282607. Epub 2017 Mar 7.
5
Design and synthesis of potent PAR-1 antagonists based on vorapaxar.基于沃拉帕沙的强效 PAR-1 拮抗剂的设计与合成。
Bioorg Med Chem Lett. 2020 Apr 15;30(8):127046. doi: 10.1016/j.bmcl.2020.127046. Epub 2020 Feb 17.
6
Vorapaxar in the secondary prevention of atherothrombosis.vorapaxar用于动脉粥样硬化血栓形成的二级预防。
Expert Rev Cardiovasc Ther. 2015 Dec;13(12):1293-305. doi: 10.1586/14779072.2015.1109447. Epub 2015 Nov 12.
7
Discovery of a vorapaxar analog with increased aqueous solubility.发现一种水溶解度增加的沃拉帕沙类似物。
Bioorg Med Chem Lett. 2010 Nov 15;20(22):6676-9. doi: 10.1016/j.bmcl.2010.09.009. Epub 2010 Sep 15.
8
Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.作为强效口服活性凝血酶受体（蛋白酶激活受体-1）拮抗剂的杂三环海巴辛类似物。
J Med Chem. 2007 Oct 18;50(21):5147-60. doi: 10.1021/jm070704k. Epub 2007 Sep 14.
9
Synthesis of novel and potent vorapaxar analogues.新型强效沃拉帕沙类似物的合成。
Org Biomol Chem. 2016 Mar 28;14(12):3264-74. doi: 10.1039/c5ob02541a.
10
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.vorapaxar对非ST段抬高型急性冠脉综合征患者血小板反应性及生物标志物表达的影响。TRACER药效学亚研究
Thromb Haemost. 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624. Epub 2014 Jan 9.
引用本文的文献
1
Multitargeting nature of muscarinic orthosteric agonists and antagonists.毒蕈碱型正构激动剂和拮抗剂的多靶点特性。
Front Physiol. 2022 Sep 6;13:974160. doi: 10.3389/fphys.2022.974160. eCollection 2022.
本文引用的文献
1
Vorapaxar in the secondary prevention of atherothrombotic events.沃拉帕沙用于动脉粥样血栓事件的二级预防。
N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.
2
Discovery of nor-seco himbacine analogs as thrombin receptor antagonists.发现诺塞考他宾类似物作为凝血酶受体拮抗剂。
Bioorg Med Chem Lett. 2012 Apr 1;22(7):2544-9. doi: 10.1016/j.bmcl.2012.01.138. Epub 2012 Feb 16.
3
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.凝血酶受体拮抗剂沃拉帕沙在急性冠脉综合征中的应用。
N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.
4
Discovery of a vorapaxar analog with increased aqueous solubility.发现一种水溶解度增加的沃拉帕沙类似物。
Bioorg Med Chem Lett. 2010 Nov 15;20(22):6676-9. doi: 10.1016/j.bmcl.2010.09.009. Epub 2010 Sep 15.
5
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.SCH 530348在非紧急经皮冠状动脉介入治疗患者中的安全性和耐受性：一项随机、双盲、安慰剂对照的II期研究。
Lancet. 2009 Mar 14;373(9667):919-28. doi: 10.1016/S0140-6736(09)60230-0.
6
Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.蛋白酶激活受体的基础与转化研究：蛋白酶激活受体1对凝血酶的拮抗作用，一种治疗动脉粥样硬化血栓形成疾病的抗血小板治疗新方法。
J Pharmacol Sci. 2008 Dec;108(4):433-8. doi: 10.1254/jphs.08r06fm.
7
Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.发现一种新型的、口服活性的基于辛可宁的凝血酶受体拮抗剂（SCH 530348），具有强效抗血小板活性。
J Med Chem. 2008 Jun 12;51(11):3061-4. doi: 10.1021/jm800180e. Epub 2008 May 1.
8
Platelet activation and atherothrombosis.血小板活化与动脉粥样硬化血栓形成。
N Engl J Med. 2007 Dec 13;357(24):2482-94. doi: 10.1056/NEJMra071014.
9
Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.作为强效口服活性凝血酶受体（蛋白酶激活受体-1）拮抗剂的杂三环海巴辛类似物。
J Med Chem. 2007 Oct 18;50(21):5147-60. doi: 10.1021/jm070704k. Epub 2007 Sep 14.
10
Himbacine derived thrombin receptor antagonists: discovery of a new tricyclic core.源自辛贝碱的凝血酶受体拮抗剂：一种新型三环核心结构的发现。
Bioorg Med Chem Lett. 2007 Jul 1;17(13):3647-51. doi: 10.1016/j.bmcl.2007.04.061. Epub 2007 Apr 25.
Zotero 插件